Lupin Limited
 |
|
| Public | |
| Traded as | : : LUPIN |
| Industry | Pharmaceuticals |
| Founded | 1968 |
| Founder | Desh Bandhu Gupta |
| Headquarters | Mumbai, Maharashtra, India |
|
Key people
|
Vinita D. Gupta, Chief Executive Officer ; Nilesh Gupta, Managing director Dr Kamal Sharma, Vice Chairman |
| Products | Pharmaceuticals, branded and generic drugs, |
| Revenue |
|
| Profit |
 $721 million USD (2016-2017) |
|
Number of employees
|
15000+ |
| Subsidiaries | Lupin Pharmaceuticals, Inc. , Kyowa Pharmaceutical Industry Co. Ltd, I’rom Pharmaceutical Co. Ltd., Pharma Dynamics, Multicare Pharmaceuticals, Generic Health Pte. Ltd. Hormosan Pharma GmbH Nanomi B.V., Laboratorios Grin, Medquimica, Biocom Russia, Temmer Germany |
| Website | www |
$2.55 billion USD (2016-2017)
Lupin Limited is a transnational pharmaceutical company based in Mumbai. It is the seventh-largest company by market capitalization; and the 10th-largest generic pharmaceutical company by revenue globally. Lupin is the fifth-largest generic pharmaceutical company in the US by prescription-led market share and 3rd largest Indian pharmaceutical company by revenue. It has the distinction of being the fastest growing generic pharmaceutical player in the US and Japan;, and is the 4th largest and the fastest growing generic pharmaceutical player in South Africa.
Lupin was founded in 1968 by Desh Bandhu Gupta, then an Associate Professor at BITS-Pilani, Rajasthan. Named after the Lupin flower because of its inherent qualities and what it personifies and stands for, the company was created with a vision to fight life-threatening infectious diseases and to manufacture drugs of the highest social priority. Gupta died on 26 June 2017 and was replaced as chairman by his wife, Manju Deshbandhu Gupta.
Lupin first gained recognition when it became one of the world’s largest manufacturers of tuberculosis drugs. The company today has a significant market share in key markets in the cardiovascular (prils and statins), Diabetology, asthma, pediatrics, CNS, GI, anti-infectives and NSAIDs therapy segments. It also has a global leadership position in the anti-TB and Cephalosporin segments.
...
Wikipedia